Boulevard Bio launches with $65M from Deerfield to advance multi-specific antibody programs for autoimmune diseases The LSX USA Congress gathers leaders from the US biotech, medtech, and healthtech sectors to network, showcase innovations, and explore partnership opportunities. The New York-based biotech debuts with quarterly-dosing antibody for kidney disease and precision immunology platform backed entirely by Deerfield Management. She studied English Literature at university and started her journalism career as a reporter and then editor of BioProcess Insider. Millie is especially interested in deals and dealmakers across the life sciences space and loves to write about the ins and outs of partnerships and investments. The clinical-stage company, backed entirely by Deerfield Management and its affiliates, is advancing three multi-specific antibody programs that aim to deliver more durable disease control with significantly less burdensome treatment schedules for patients managing chronic autoimmune conditions.

Original title: “Boulevard Bio exits stealth with $65m funding”

The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.

Original title: “Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers”

New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.

Original title: “Biotech initiatives pick up as more regions race to become hubs”

Companies that manufacture MDMA and psilocybin for patients in other countries are looking to use their experience to access the potential U.S. market.

Original title: “Nascent US psychedelic therapy opportunity attracts overseas manufacturers”

The terms of the agreement with Royalty Pharma suggest the market potential of Zealand Pharma’s polycythemia vera drug candidate may be undervalued, according to Jefferies analysts.

Original title: “Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M”

Avalyn Pharma and Generate Biomedicines executives discuss the long hours, hard work and rewarding moments of taking their companies public.

Original title: “Behind the bell: gearing up to go public”

Last month, biopharmas cutting or planning to cut their workforces included Amgen, GSK and Novartis, with Novartis’ layoffs affecting the most people.

Original title: “July's biopharma layoffs affect 466 employees, a 94% year-over-year drop”